Reports


Japan Gemcitabine HCl Market and Forecast 2020-2026

  • TBI42768
  • October 19, 2020
  • Japan
  • 132 pages
  • ROIF Expert
                                              Gemcitabine Hydrochloride is the hydrochloride salt of an analog of the antimetabolite nucleoside deoxycytidine with antineoplastic activity.

Gemcitabine Injection (the generic equivalent of Eli Lilly's, Gemzar®), available in 200mg/5.26mL, 1G/26.3mL and 2G/52.6mL; has an approximate market size of $25M, annually.

Gemcitabine is a nucleoside analog used as chemotherapy. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the "faulty" nucleoside, resulting in apoptosis (cellular "suicide"). Even though it involves cell death, apoptosis serves a healthy and protective role in our bodies.

Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being researched for use in oesophageal cancer and is used on case to case basis in lymphomas and various other tumor types.

Synonyms for Gemcitabine are Gemcitabin(German), Gemcitabina (Spanish), and Gemcitabinum (Latin).

Market Analysis and Insights: Global Gemcitabine HCl Market

This report focuses on Global Gemcitabine HCl market.
The Japan Gemcitabine HCl market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Japan Gemcitabine HCl Scope and Market Size

Gemcitabine HCl market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Gemcitabine HCl market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Gemcitabine HCl market is segmented into
  • Above 98%
  • Below 98%
Segment by Application, the Gemcitabine HCl market is segmented into
  • Non-Small Cell Lung Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Other
Regional and Country-level Analysis The Gemcitabine HCl market is analyzed and market size information is provided by regions (countries). The key regions covered in the Gemcitabine HCl market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. The report includes a country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026. Competitive Landscape and Gemcitabine HCl Market Share Analysis Gemcitabine HCl market competitive landscape provides details and data information by players. The report offers a comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Gemcitabine HCl business, the date to enter into the Gemcitabine HCl market, Gemcitabine HCl product introduction, recent developments, etc. The major vendors covered:
  • Sun Pharmaceutical Industries
  • Tapi Teva
  • Accord Healthcare Inc.
  • Actavis Pharma Company
  • Agila Jamp Canada Inc
  • Armas Pharmaceuticals Inc.
  • Athenex Pharmaceutical Division, Llc.
  • BluePoint Laboratories
  • CHIATAI QINGJIANG
  • Dr Reddy's Laboratories
  • Fresenius Kabi
  • FUAN PHARMACEUTICAL
  • Gland Pharma Limited
  • Heritage Pharmaceuticals Inc.
  • HISUN
  • Hospira, Inc.
  • Huachu Industrial
  • Jierui Pharmaceutical
  • Jinkang Pharmaceutical Technology
  • Meitheal Pharmaceuticals Inc.
  • Mylan Laboratories Limited
  • NorthStar Rx LLC
  • Sagent Pharmaceuticals
  • Sandoz Canada Incorporated
  • Shilpa Medicare
  • Taro Pharmaceuticals, Inc.
  • Teligent Ou
  • Zhendong Group

Table of Contents

Chapter 1. Preface
	
		1.1. Report Description
		
			1.1.1. Objective
			1.1.2. Target Audience
			1.1.3. Unique Selling Proposition (USP) & Offerings
		
		
		1.2. Research Scope
		1.3. Research Methodology
		
			1.3.1. Market Research Process
			1.3.2. Market Research Methodology
			1.3.3. Level 1: Primary Research
			1.3.4. Level 2: Secondary Research
			1.3.5. Level 3: Data Validation and Expert Panel Assessment Report Description and Scope
			
Chapter 2. Executive Summary
	
		2.1. Global Japan Gemcitabine HCl 2019-2029 (USD Billion)
		2.2. Global Japan Gemcitabine HCl: Market Snapshot
	 
Chapter 3. Global Japan Gemcitabine HCl - Industry Analysis
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form

 

Related Reports